JP3930923B2 - Obsidian external composition - Google Patents
Obsidian external composition Download PDFInfo
- Publication number
- JP3930923B2 JP3930923B2 JP24550896A JP24550896A JP3930923B2 JP 3930923 B2 JP3930923 B2 JP 3930923B2 JP 24550896 A JP24550896 A JP 24550896A JP 24550896 A JP24550896 A JP 24550896A JP 3930923 B2 JP3930923 B2 JP 3930923B2
- Authority
- JP
- Japan
- Prior art keywords
- obsidian
- weight
- parts
- composition
- fired product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、パップ剤等の貼付剤、軟膏などの外用組成物に関する
【０００２】
【従来の技術】
従来、無機化合物で医薬品として外用剤に利用されているものには、カオリン、ベントナイト、合成ケイ酸アルミニウム等があるが、薬効に優れた作用が見い出されるものは少なく、賦形剤としての利用に止まっている場合が多い。
例えば、医薬品として従来カオリン、ベントナイト等がパップ剤等において用いられているが、その作用はある程度の吸水効果ないしは冷却効果を期待するものであり、また、その保形性を保つことを主たる目的として用いられている。
一方、黒曜石は、屋上、人口地盤および滞水、透湿地盤の造園緑地化用保水排水骨材として用いられているが、医薬品関係では特開昭５５−１００３０１号公報に、防虫、防腐資材への利用が開示されているのみである。
【０００３】
【発明が解決しようとする課題】
本発明は、パップ剤等の貼付剤、軟膏などの外用剤に配合して有効な新規な無機化合物を提供することを目的とする。
【０００４】
【課題を解決するための手段】
本発明は、従来発見されていなかった黒曜石にその特性を見い出したことに基づいたものであり、具体的には▲１▼黒曜石はそれ自身外用剤として用いられることにより強い抗炎症作用を示すこと、▲２▼黒曜石を外用組成物に配合することその物性的特性に優れていることを見い出したものである。
すなわち、本発明の外用組成物は、黒曜石を粉砕し焼成して調製した粉末状黒曜石焼成物を配合することを特徴とする。
【０００５】
【発明の実施の形態】
黒曜石の主な化学成分の組成は、ＳｉＯ2 ７０〜８０％、Ａｌ2Ｏ3１２〜１８％、Ｋ2Ｏ ２〜５％、Ｎａ2Ｏ ２〜５％である。黒曜石を焼成して得られる黒曜石焼成物は、黒曜石の成分、焼成時の黒曜石の粒度、形状、焼成温度、焼成後の粉砕条件によっても異なるが、焼成過程でその空隙率、粒子径等を調整することができ、それにより物性面の適正化を図り、外用組成物に添加用の粉末状素材として利用価値の高いものとすることができる。具体的には、焼成により黒曜石の軽量化が可能となり、超軽量化された黒曜石焼成物が得られる。この超軽量化黒曜石焼成物の嵩密度は０．０５〜０．２ｇ／ｃｃが適当である。
【０００６】
黒曜石の焼成温度は、１，０００℃の高温も可能であるが、９０〜４００℃が好ましく、嵩密度、粒表面の状況を調整することができる。
本発明の黒曜石焼成物は、黒曜石を粉砕し、焼成し、さらに必要に応じて粉砕し、粒度を調整することにより製造することができる。
本発明の外用組成物は、黒曜石を焼成して得た黒曜石焼成物（粉末状素材）を、従来のパップ剤等の貼布剤、軟膏などの外用基剤に配合することにより得られ、その配合量は、例えばパップ剤では１〜４５重量％、軟膏では１〜４５重量％である。
【０００７】
【発明の効果】
本発明の黒曜石焼成物は、従来の無機系配合剤であるカオリン等とは作用が本質的に異なり、全く新規な用途を開発した発明である。
本発明の粉末状黒曜石焼成物を外用剤、特に貼付剤に配合した場合、黒曜石固有の性質として優れた抗炎症効果が得られ、また物性面においても透水性と保水性とのバランスが保たれ、保水性の持続力に対しても卓越した効果を示す。
【０００８】
【実施例】
実施例１
黒曜石を粉砕後、２００℃で加熱焼成し、この焼成物を更に粉砕した粉末状の黒曜石焼成物を得た。
この黒曜石焼成物４０重量部を精製水２９．２重量部及びＤ−ソルビトール（７０％液）２２．０重量部に分散し、エデト酸ナトリウム０．１重量部を加えた後、酒石酸を０．５重量部、安息香酸ナトリウム０．１重量部を加えてよく撹拌し組成Ａとする。
一方、別にマクロゴール４００を４．０重量部秤り取り、ポリアクリル酸部分中和物４．０重量部を入れて分散した後、ジヒドロキシアルミニウムアミノアセテート０．１重量部を混和して組成Ｂとした。
この組成Ｂを先の組成Ａに加えて撹拌混合した後、この組成物をシート状に展延して実施例１の貼布剤（パップ剤）とした。
【０００９】
実施例２
黒曜石を粉砕後、２５０℃で加熱焼成処理し、得られた焼成物を更に粉砕して粉末状の黒曜石焼成物を得た。
この黒曜石焼成物８重量部を、精製水４５．２重量部及びＤ−ヒルビトール（７０％液）２０重量部およびグリセリン１８重量部に分散し、エデト酸ナトリウム０．１重量部を加えた後、酒石酸を０．５重量部、安息香酸ナトリウムを０．１重量部加えてよく撹拌し、組成Ａとする。
一方、別にマクロゴール４００を４．０重量部秤り取り、ポリアクリル酸部分中和物４．０重量部を入れて分散した後、ジヒドロキシアルミニウムアミノアセテート０．１重量部を混和して組成Ｂとした。
この組成Ｂを先の組成Ａに加えて撹拌混合した後、シート上に展延して実施例２の本発明の貼付剤（パップ剤）を製造した。
【００１０】
実施例３
黒曜石を粉砕後、２００℃で加熱焼成し、この焼成物を更に粉砕して粉末状の黒曜石焼成物を得た。
この黒曜石焼成物４０重量部および安息香酸ナトリウム０．１重量部を精製水５１．９重量部に分散し、これにマクロゴール４００ ４重量部にカルボキシビニルポリマー４．０重量部を分散した溶液をすばやく加えて撹拌混合し、本発明の実施例３の軟膏を製造した。
【００１１】
実施例４
黒曜石を粉砕後、２５０℃で加熱焼成し、この焼成物を更に粉砕して粉末状の黒曜石焼成物を得た。
黒曜石焼成物５重量部および安息香酸ナトリウム０．１重量部を精製水７３重量部に分散し、これに４重量部のマクロゴール４００およびプロピレングリコール１０重量部にカルボキシビニルポリマー７．９重量部を分散した溶液をすばやく加えて撹拌混合し、軟膏とした。
【００１２】
比較例１
実施例１の黒曜石焼成物の代わりにカオリンを用いる以外は、実施例１と同様にして貼付剤を製造した。
【００１３】
実験例１（カラゲニン浮腫法）
（１）実験方法
Ｗｉｓｔａｒ系雄性ラット（５週齢、体重１２０〜１４５ｇ）を４群に分け、試験３日前に、ラット右足に脱毛クリームを塗布して除毛した。
試験当日、ラット右後足容積を、足容積測定装置を用いて測定した。
エーテル麻酔と、１％カラゲニン生理食塩水懸濁液（試験当日作成）を０．１ｍｌ右足皮下に投与し炎症を惹起させた。カラゲニン注射２．０時間後および４．０時間後に再度ラット右足容積を測定し、下記の数１により浮腫率を測定算出した。
【００１４】
【数１】
なお、被験剤薬（貼付剤３×４ｃｍ）はカラゲニン注射直後および各測定容積測定時間で足容積測定後に、新たな被験薬剤を適用した。また、試験開始からラットは個別ケージに入れ、頭部に布製フードを被せて保定した。
各投与群のカラゲニン注射２時間後の浮腫率を測定算出しその結果を下記の表１に、また同４時間後の結果を表２に示す。さらに、Ｔｕｒｋｙの方法により、２時間、４時間後の浮腫率の各群間の多重比較を行なった結果を表３に示す。
実験結果
（黒曜石配合貼付剤のカラゲニン足浮腫抑制試験）
【００１６】
【表１】
【表２】
【表３】
黒曜石を配合した貼付剤、特にパップ剤においては、抗炎症作用の実験によって対象群やカオリンのみの基剤群に比し、有意な浮腫抑制効果を得ており、又、黒曜石単独の使用で、市販パップ剤（セイヨウトチノミエキス、サリチル酸グリコール、サリチル酸ジフェンヒドラミン、ｄｌカンフル、メントール配合）と有意の差がなく効果を示した。また、本発明の黒曜石配合外用組成物は物性値ににおいてカオリンに比べ、外用適用への有用性が高いことを見いだしている。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a composition for external use such as patches and ointments such as cataplasms.
[Prior art]
Conventionally, kaolin, bentonite, synthetic aluminum silicate, etc. are used as external medicines as pharmaceuticals as inorganic compounds, but few of them have an excellent medicinal effect and are used as excipients. Often stopped.
For example, kaolin, bentonite, etc. are conventionally used in pharmaceuticals as a pharmaceutical, but its action is expected to have some water absorption effect or cooling effect, and the main purpose is to maintain its shape retention. It is used.
On the other hand, obsidian is used as a retention and drainage aggregate for landscaping greening of rooftops, artificial ground and water permeable grounds, and moisture-permeable grounds. The use of is only disclosed.
[0003]
[Problems to be solved by the invention]
It is an object of the present invention to provide a novel inorganic compound that is effective when blended with an external preparation such as a patch such as a poultice or an ointment.
[0004]
[Means for Solving the Problems]
The present invention is based on the discovery of the characteristics of obsidian, which has not been discovered in the past. Specifically, (1) Obsidian itself exhibits a strong anti-inflammatory effect by being used as an external preparation. (2) It has been found that blending obsidian into a composition for external use has excellent physical properties.
That is, the composition for external use of the present invention is characterized by blending a powdered obsidian fired product prepared by crushing and firing obsidian.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
The composition of the main chemical components of obsidian, SiO 2 70~80%, Al 2 O 3 12~18%, K 2 O 2~5%, a Na 2 O 2~5%. Obsidian fired products obtained by firing obsidian vary depending on the composition of obsidian, particle size, shape, firing temperature, and firing conditions after firing, but the porosity, particle size, etc. are adjusted during the firing process. Thus, the physical properties can be optimized, and it can be highly useful as a powdery material for addition to the external composition. Specifically, obsidian can be reduced in weight by firing, and an obsidian fired product having an ultra-light weight can be obtained. The bulk density of the ultralightweight obsidian fired product is suitably 0.05 to 0.2 g / cc.
[0006]
The obsidian firing temperature can be as high as 1,000 ° C., but 90 to 400 ° C. is preferable, and the bulk density and the condition of the grain surface can be adjusted.
The obsidian fired product of the present invention can be produced by pulverizing and firing obsidian, further pulverizing it as necessary, and adjusting the particle size.
The composition for external use of the present invention is obtained by blending an obsidian fired product (powder-like material) obtained by firing obsidian into an external base such as a conventional patch or ointment. The blending amount is, for example, 1 to 45% by weight for a poultice and 1 to 45% by weight for an ointment.
[0007]
【The invention's effect】
The obsidian fired product of the present invention is an invention in which the action is essentially different from that of kaolin or the like, which is a conventional inorganic compounding agent, and a completely new application has been developed.
When the powdered obsidian calcined product of the present invention is blended into an external preparation, particularly a patch, an excellent anti-inflammatory effect is obtained as an inherent property of obsidian, and the balance between water permeability and water retention is also maintained in terms of physical properties. In addition, it has an excellent effect on the sustainability of water retention.
[0008]
【Example】
Example 1
The obsidian was pulverized and then fired at 200 ° C. to obtain a powdered obsidian fired product obtained by further grinding the fired product.
40 parts by weight of this obsidian fired product was dispersed in 29.2 parts by weight of purified water and 22.0 parts by weight of D-sorbitol (70% solution), 0.1 parts by weight of sodium edetate was added, and then tartaric acid was added in an amount of 0. Add 5 parts by weight and 0.1 part by weight of sodium benzoate and stir well to obtain composition A.
Separately, 4.0 parts by weight of Macrogol 400 was weighed and 4.0 parts by weight of polyacrylic acid partial neutralized product was dispersed therein, and then 0.1 parts by weight of dihydroxyaluminum aminoacetate was mixed to form composition B. It was.
After adding this composition B to the previous composition A and stirring and mixing, this composition was spread in a sheet shape to obtain a patch of Example 1 (a poultice).
[0009]
Example 2
The obsidian was pulverized and then heated and fired at 250 ° C., and the obtained fired product was further pulverized to obtain a powdered obsidian fired product.
After 8 parts by weight of this obsidian fired product was dispersed in 45.2 parts by weight of purified water, 20 parts by weight of D-hirbitol (70% solution) and 18 parts by weight of glycerin, 0.1 parts by weight of sodium edetate was added, Add 0.5 parts by weight of tartaric acid and 0.1 parts by weight of sodium benzoate and stir well to obtain composition A.
Separately, 4.0 parts by weight of Macrogol 400 was weighed and 4.0 parts by weight of polyacrylic acid partial neutralized product was dispersed therein, and then 0.1 parts by weight of dihydroxyaluminum aminoacetate was mixed to form composition B. It was.
This composition B was added to the previous composition A, mixed with stirring, and then spread on a sheet to produce the patch of the present invention (patch) of Example 2.
[0010]
Example 3
The obsidian was pulverized and then fired at 200 ° C., and the fired product was further pulverized to obtain a powdered obsidian fired product.
A solution in which 40 parts by weight of the burned obsidian and 0.1 parts by weight of sodium benzoate are dispersed in 51.9 parts by weight of purified water, and 4.0 parts by weight of carboxyvinyl polymer in 4 parts by weight of Macrogol 400 is dispersed therein. The ointment of Example 3 of the present invention was produced by quickly adding and stirring and mixing.
[0011]
Example 4
The obsidian was pulverized and then heated and fired at 250 ° C., and the fired product was further pulverized to obtain a powdered obsidian fired product.
5 parts by weight of burnt obsidian and 0.1 parts by weight of sodium benzoate are dispersed in 73 parts by weight of purified water, and 4 parts by weight of Macrogol 400 and 10 parts by weight of propylene glycol are mixed with 7.9 parts by weight of carboxyvinyl polymer. The dispersed solution was quickly added and mixed with stirring to obtain an ointment.
[0012]
Comparative Example 1
A patch was produced in the same manner as in Example 1 except that kaolin was used instead of the obsidian fired product of Example 1.
[0013]
Experimental example 1 (carrageenan edema method)
(1) Experimental Method Wistar male rats (5 weeks old, body weight 120-145 g) were divided into 4 groups, and the hair was removed by applying a hair removal cream to the right leg of the rat 3 days before the test.
On the day of the test, the rat right hind paw volume was measured using a paw volume measuring device.
Ether anesthesia and 1% carrageenan physiological saline suspension (prepared on the test day) were administered subcutaneously in 0.1 ml right foot to induce inflammation. The rat right paw volume was measured again 2.0 hours and 4.0 hours after carrageenin injection, and the edema rate was measured and calculated by the following formula 1.
[0014]
[Expression 1]
In addition, a new test drug was applied to the test drug (patch 3 × 4 cm) immediately after the carrageenin injection and after the foot volume measurement at each measurement volume measurement time. In addition, from the start of the test, the rats were placed in individual cages and covered with a cloth hood on the head.
The edema rate at 2 hours after carrageenin injection in each administration group was measured and calculated. The results are shown in Table 1 below, and the results after 4 hours are shown in Table 2. Further, Table 3 shows the results of multiple comparison between groups of edema rates after 2 hours and 4 hours by the method of Turky.
Experimental results (carrageenin paw edema suppression test using obsidian patch)
[0016]
[Table 1]
[Table 2]
[Table 3]
In the patch containing obsidian, especially the cataplasm, compared to the target group and the base group of kaolin alone, a significant edema suppression effect has been obtained by the experiment of anti-inflammatory action, and by using obsidian alone, It showed an effect with no significant difference from a commercially available poultice (containing horse chestnut extract, salicylic acid glycol, diphenhydramine salicylate, dl camphor and menthol). Further, the obsidian blended external composition of the present invention has been found to be more useful for external application in terms of physical properties than kaolin.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24550896A JP3930923B2 (en) | 1996-08-28 | 1996-08-28 | Obsidian external composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24550896A JP3930923B2 (en) | 1996-08-28 | 1996-08-28 | Obsidian external composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1072341A JPH1072341A (en) | 1998-03-17 |
| JP3930923B2 true JP3930923B2 (en) | 2007-06-13 |
Family
ID=17134729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24550896A Expired - Lifetime JP3930923B2 (en) | 1996-08-28 | 1996-08-28 | Obsidian external composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3930923B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7295310B1 (en) * | 2022-05-23 | 2023-06-20 | 花王株式会社 | STRUCTURE FOR CASTING MANUFACTURING, MANUFACTURING METHOD THEREOF, AND METHOD OF MANUFACTURING CASTING USING THE SAME |
-
1996
- 1996-08-28 JP JP24550896A patent/JP3930923B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1072341A (en) | 1998-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102386665B1 (en) | Pharmaceutical formulation of palbociclib and manufacturing method thereof | |
| JP2007500713A (en) | Bioactive composition containing triazine | |
| Gaikwad et al. | Enhancement in in vitro anti-angiogenesis activity and cytotoxicity in lung cancer cell by pectin-PVP based curcumin particulates | |
| JP5232472B2 (en) | Pranlukast solid dispersion composition with improved bioavailability and method for producing the solid dispersion | |
| JPH02237922A (en) | Antiviral agent | |
| JPH02131426A (en) | Percutaneous administrative preparation containing bunazosin or its salt | |
| EP1809274B1 (en) | Pharmaceutical composition for rectal or vaginal application comprising a platinum complex | |
| WO2007014754A1 (en) | Process for the preparation of liposomal formulations | |
| CN111514306B (en) | Fullerene nano-particles for enhancing anti-tumor immunotherapy | |
| CA1203480A (en) | Compressed products with retarded release of active substance | |
| TWI740045B (en) | Insoluble complex or its solvate, pharmaceutical composition and application thereof | |
| JP3930923B2 (en) | Obsidian external composition | |
| HU208495B (en) | Process for producing retarde pharmaceutical compositions | |
| JPH05105628A (en) | Antiinflammatory analgesic for external use | |
| CN106265536A (en) | Bortezomib pharmaceutical composition and preparation method thereof | |
| JPS6158446B2 (en) | ||
| RU2494733C1 (en) | Pharmaceutical composition of phytonutrients having high bioavailability and possessing anti-cancer activity, and method for preparing it (versions) | |
| CN110041325A (en) | Berberine hydrochloride and brufen eutectic object and preparation method and its composition and purposes | |
| JPH11171768A (en) | Antiphlogistic-sedative medicine for external use | |
| CN100512807C (en) | Pharmaceutical for preventing and curing acute gout, tumor and hepatic/pulmonary fibrosis and preparation method thereof | |
| CN107126417A (en) | A kind of curcuma zedoary alcohol solid dispersoid and its oral solid formulation | |
| JP3540246B2 (en) | External anti-inflammatory analgesic patch | |
| JPH0616556A (en) | Slightly soluble medicine-containing preparation | |
| JPS6165819A (en) | Drug composition containing organic germanium compound | |
| JP3777392B2 (en) | Anti-inflammatory analgesic body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070220 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070312 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100316 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110316 Year of fee payment: 4 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120316 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120316 Year of fee payment: 5 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130316 Year of fee payment: 6 |